Bartosz Kopeć, Mateusz Sikora, Tomasz Sroczyński, Andrzej Pawlik
The role of Janus kiases inhibitor tofacinib in the therapy of selected, chronic inflammatory diseases
Along with development of medical knowledge, resorces of available options of treatment for rheumatoid arthritis, inflammatory bowel diseases and psoriasis are becoming greater. It is possible thanks to better understanding of physiology and patophysiology of inflammatory diseases. Knowing the metabolic pathways of transduced signal, initiated by cytokines, we could modulate and stop cell’s response what would lead to decrease of symptoms and disease progress. Janus kinases are intracell proteins which are pivotal in accepitng extracellular signals and transducing them into the nuclues what lead to genes’ expression change. Inhibition of this process by tofacinib – Janus kinases inhibitor – seems to bring positive results in the treatment of inflammatory diseases and could be potential line of treatment for patients who have not benefited from past therapy.
Keywords: Janus kiases, tofacitinib, inflammation.
© Farm Pol, 2019, 75(4): 181–184